Poolbeg Pharma has announced FY 2023 results to end December 2023, which positively reflect the company’s capital-efficient operating model with net cash of £12.2m being reported, significantly ahead of our expectations (2023E: £10.9m). Meaningful R&D progress whilst maintaining financial prudence means that Poolbeg enters 2024 with a strong balance sheet in absolute terms and relative to many biotech peers, with a cash runway (to fund the existing R&D pipeline) we forecast will extend into 2026 ....
30 Apr 2024
Poolbeg Pharma - FY 2023 results: Financial discipline provides runway into 2026
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Poolbeg Pharma - FY 2023 results: Financial discipline provides runway into 2026
Poolbeg Pharma PLC (POLB:LON) | 12.8 0 0.0% | Mkt Cap: 64.0m
- Published:
30 Apr 2024 -
Author:
Chris Donnellan | Adam McCarter -
Pages:
15
Poolbeg Pharma has announced FY 2023 results to end December 2023, which positively reflect the company’s capital-efficient operating model with net cash of £12.2m being reported, significantly ahead of our expectations (2023E: £10.9m). Meaningful R&D progress whilst maintaining financial prudence means that Poolbeg enters 2024 with a strong balance sheet in absolute terms and relative to many biotech peers, with a cash runway (to fund the existing R&D pipeline) we forecast will extend into 2026 ....